8 June 2011
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Annual General Meeting and Trading Update
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting at 11.00 today.
Dr. Don Evans, Chairman of the Company, will make the following comments on its current trading.
“I am pleased to report that the good start to the year, as highlighted in the 2010 Preliminary Results announcement on 8 March 2011, is continuing.
Feedback from our partners in the US market on LiquiBand® continues to be very positive, with end user sales showing strong growth quarter-on-quarter. It is however important to reiterate that ex-factory sales in 2010 benefited from significant sampling and customer evaluation orders and that this will distort comparisons of LiquiBand® sales from 2010 to 2011. In this regard, sampling and customer evaluations are continuing, and we remain pleased with the rate at which hospitals are converting to regular usage. Overall, the Board is confident that AMS is well placed to grow its US market share and build a strong, global brand for LiquiBand®.
Elsewhere, our other key drivers for growth are also performing well. Our rebranding of ActivHeal® and its positioning for use on routine wounds is becoming better understood by practitioners and good progress is being maintained. Our foam business continues to grow well and we remain committed to the strategy of upgrading our processes and materials in order to deliver further value to the Group. Our partners continue to drive our silver alginate business forward, despite the slow-down in market growth rates.
Whilst global economic conditions continue to be challenging, the Board is pleased to confirm that trading is in line with current market expectations for the full year 2011 and we remain confident about the long term prospects for the Group.”
– ends –
For further enquiries:
Advanced Medical Solutions Group plc +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Mary Tavener, Finance Director
Tavistock Communications +44 (0) 20 7920 3150
John West / Chris Munden / Andrew Dunn
Investec Bank plc +44 (0) 20 7597 5970
Gary Clarence / Patrick Robb / Daniel Adams
Notes to Editors:
AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.
AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.
This information is provided by RNS